Literature DB >> 11012586

Cutaneous leishmaniasis.

N C Hepburn1.   

Abstract

Leishmaniasis is a major World health problem, which is increasing in incidence. In Northern Europe it is seen in travellers returning from endemic areas. The protozoa is transmitted by sandflies and may produce a variety of clinical syndromes varying from a simple ulcer to fatal systemic disease. This review considers the management of simple cutaneous leishmaniasis. Patients usually have a single ulcer which may heal spontaneously, requiring only topical, or no treatment at all. Lesions caused by Leishmania braziliensis may evolve into the mucocutaneous form, 'espundia', and should be treated with systemic antimony. Sodium stiboglucoante 20 mg/kg/day i. v. for 20 days is the appropriate first line treatment in these cases. Although it may cause transient bone marrow suppression, liver damage, a chemical pancreatitis, and disturbances in the electrocardiogram, it appears to be safe. The success of treatment should be assessed 6 weeks after it has been completed and patients should be followed up for 6 months.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012586     DOI: 10.1046/j.1365-2230.2000.00664.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  19 in total

1.  [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].

Authors:  M J Flaig; J Rupec; T Ruzicka; R A Rupec
Journal:  Hautarzt       Date:  2007-08       Impact factor: 0.751

2.  In vitro activities of hexaazatrinaphthylenes against Leishmania spp.

Authors:  Atteneri López-Arencibia; Daniel García-Velázquez; Carmen M Martín-Navarro; Ines Sifaoui; María Reyes-Batlle; Jacob Lorenzo-Morales; Ángel Gutiérrez-Ravelo; José E Piñero
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

Review 3.  [Cutaneous leishmaniasis].

Authors:  C D Enk; K Gardlo; M Hochberg; A Ingber; T Ruzicka
Journal:  Hautarzt       Date:  2003-04-18       Impact factor: 0.751

4.  New world cutaneous leishmaniasis treated with intralesional injection of pentavalent antimony.

Authors:  Ji Yeon Shin; Young Bok Lee; Baik Kee Cho; Hyun Jeong Park
Journal:  Ann Dermatol       Date:  2013-02-14       Impact factor: 1.444

5.  The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation.

Authors:  Maxime Hallé; Maria Adelaida Gomez; Matthew Stuible; Hidehisa Shimizu; W Robert McMaster; Martin Olivier; Michel L Tremblay
Journal:  J Biol Chem       Date:  2008-12-08       Impact factor: 5.157

6.  In vitro activity of Alkanna frigida extracts in comparison with glucantime against Leishmania major.

Authors:  Fariba Jafari; Abbasali Nourian; Asghar Fazaeli; Alireza Yazdinezhad; Ali Haniloo
Journal:  Iran J Microbiol       Date:  2013-06

7.  Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis.

Authors:  Pouran Layegh; Omid Rajabi; Mahmoud Reza Jafari; Parisa Emamgholi Tabar Malekshah; Toktam Moghiman; Hami Ashraf; Roshanak Salari
Journal:  J Parasitol Res       Date:  2011-11-24

8.  Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Authors:  Viroj Wiwanitkit
Journal:  Ther Clin Risk Manag       Date:  2012-06-22       Impact factor: 2.423

9.  Ultrasound patterns of localized cutaneous leishmaniasis and clinical correlations.

Authors:  Andrea Sechi; Iria Neri; Annalisa Patrizi; Ambra Di Altobrando; Roberta Clinca; Raffaele Dante Caposiena Caro; Miriam Leuzzi; Cosimo Misciali; Valeria Gaspari
Journal:  J Ultrasound       Date:  2021-02-01

10.  Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response.

Authors:  Anja Kathrin Wege; Christian Florian; Wolfgang Ernst; Nicole Zimara; Ulrike Schleicher; Frank Hanses; Maximilian Schmid; Uwe Ritter
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.